Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer

Title:Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer

Volume: 21

Author(s): Eknath Kole, Krishna Jadhav, Raghuraj Singh, Shilpa Mandpe, Ashwin Abhang, Rahul K. Verma and Jitendra Naik*

Affiliation:

• Department of Pharmaceutical Technology, University Institute of Chemical Technology, KBC North Maharashtra University, Jalgaon M.S. 425001, India

Abstract: The advent of drug resistance in response to epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitor (TKI) targeted therapy represents a serious challenge in the management of non-small cell lung cancer (NSCLC). These acquired resistance mutations, attributed to several advanced EGFR mutations and, necessitated the development of new-generation TKIs. Nanomedicine approaches provide a plausible way to address these problems by providing targeted delivery and sustained release, which have demonstrated success in preclinical trials. This review article provides a summary of nano-formulations designed for EGFR-TKI-resistant NSCLC, highlighting their efficacy in both in vitro and in vivo models. These findings reveal insights into the design of nanoparticles and multifunctional nanosystems, offering a potential avenue for efficacious treatment of EGFR-TKIresistant NSCLC.

Cite this article as:

Kole Eknath, Jadhav Krishna, Singh Raghuraj, Mandpe Shilpa, Abhang Ashwin, Verma Rahul K. and Naik Jitendra*, Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer, Current Drug Delivery 2024; 21 () . https://dx.doi.org/10.2174/0115672018278617231207051907